VR and AR Examined from All Angles at IBC2017
Virtual Reality (VR), Augmented Reality (AR) and Mixed Reality (MR) will come under real-world scrutiny at IBC2017, with opportunities throughout the show to learn more about these new technologies - from their current place in the market to the opportunities they offer, as well as examining technological challenges and user experiences.
Rikard Steiber, President Viveport and SVP Virtual Reality at HTC Vive, will give a conference keynote presentation on 16 September looking at the road ahead for VR. The session will look at the emerging swathe of consumer devices and services, such as the Viveport VR app store, as well as showcasing successful VR experiences across platforms, from entertainment to sports content.
While revenue forecasts for VR and AR over the next three years run into the billions, many companies are still hesitant to invest. The panel discussion “Leaving the Hype Behind: Next Frontier in VR, AR, MR and Other Realities in Between” on 17 September, promises an illuminating session on the realities of VR and AV. Success stories, insight into the projects in R&D, and a pragmatic discussion about what will it take for VR and AR technologies to reach their potential will all feature. Panellists include Edward Tang, Co-Founder and CTO of Avegant, a company that has developed ground-breaking Retinal Imaging Technology; Leen Segers, Co-Founder and CEO of LucidWeb, a pioneer in VR content development and distribution; and Tony Mugavero, CEO of LittlStar, a global network platform dedicated to VR and 360 content.
Also taking place on 17 September, the Startup Forum offers an invaluable day for established media houses, startups and investors working in VR, AR and MR to share their opinions on the future for these advanced media technologies. Speakers include Marco DeMiroz, Co-Founder of The Venture Reality Fund (The VR Fund), a company that invests in early-stage VR, AR and MR startups.
IBC has also curated a choice selection of conference papers on this hot topic, in a session entitled “VR and AR – The Production, The Potential and The Pitfalls”. Speakers will share some of the lessons that have been learned so far, as well as discussing the exciting potential of live-action VR captured with camera arrays, the potential adverse effects of VR and AR – and how to avoid them.
In addition, the IBC Future Zone is set to deliver the latest ideas and innovations as a specially selected group of companies, including BBC R&D, Generic Robotics, NHK. Sennheiser and Immersia TV, showcases technologies including mixed reality, 3D audio and holographic projection, with a focus on multi-sensory virtual worlds and imagery of the future.
The IBC Future Zone is also home to the IBC Future Reality Theatre. Free to attend for all IBC attendees, the Theatre looks beyond current technology, identifying state of the art concepts and inventions and helping to map future applications and market sectors. Confirmed companies speaking include, Adobe, Live Planet, Nokia, V-Nova and Mettle.
“VR, AR and MR are everywhere at IBC this year, from the conference to the Future Zone to the exhibition halls,” said Michael Crimp, CEO, IBC. “There’s a real sense of excitement around these new technologies and IBC provides an ideal opportunity to learn more about the new opportunities that are available for driving innovative content and creating new revenue streams.”
## ENDS ##
Notes to Editors:
IBC is the world’s leading media, entertainment and technology show. It attracts 55,000+ attendees from more than 170 countries and combines a highly respected and peer-reviewed conference with an exhibition that showcases more than 1,700 leading suppliers of state of the art electronic media and entertainment technology.
Conference: 14 – 18 September 2017
Exhibition: 15 – 19 September 2017
For more information about IBC2017 visit: show.ibc.org/
T: +44 7718 985 252
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases18.11.2017 23:00 | Pressemelding
AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 18:20 | Pressemelding
AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute
Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 09:11 | Pressemelding
The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other
Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn17.11.2017 16:20 | Pressemelding
Madison Realty Capital (MRC) announced the closing of a $64.0 million construction loan for 200 Kent Avenue, a 117,326 square foot mixed-use development located in Williamsburg, Brooklyn. The retail portion of the property, which will include over 600 feet of frontage, will be anchored by a popular national grocery chain. Overall, the project will offer 50,101 square feet of retail space, 22,055 square feet of office and restaurant space, and 45,170 square feet of parking. “We continue to establish MRC as the one-stop shop for financing transitional real estate, including ground-up development deals like 200 Kent Avenue,” said Josh Zegen, Co-Founder and Managing Principal of MRC. “In this case, we’re working with a repeat MRC borrower who understands our ability to execute efficiently, given our firm’s up-to-the minute knowledge of local market conditions and non-bureaucratic approach to
Ncardia Announces Completion of €10.5M Investment Round17.11.2017 12:31 | Pressemelding
Ncardia, an emerging drug discovery and development stem cell technology company whose mission is to deliver cardiac and neural solutions based on its best-in-class human induced pluripotent stem cell (iPSC)-derived technology, today announced the completion of a €10.5 million series B financing round. The round was led by Épimède, a Belgium venture capital firm. Ncardia is a privately-held company with operations in Europe and the US, that produces and commercializes high-quality, fully-functional human iPSC-derived cardiovascular and neuronal cell types. Using its cell products, Ncardia develops and commercializes assay services for drug safety and efficacy testing. Additionally the company has built up a strong portfolio of patents covering the use of stem cell models for these applications. Stefan Braam, CEO of Ncardia, commented: “At Ncardia, important progress h
Double Win for Vocalink at the 2017 Payments Awards17.11.2017 09:35 | Pressemelding
Vocalink, a Mastercard company, was last night awarded with two prestigious awards - The Overall Winner and the Payments Infrastructure of the Year Award, for its leading technology and expertise, and in recognition for a milestone year that saw Vocalink’s solutions transform the way people and businesses move money across the globe. 2017 saw Vocalink deliver ground-breaking immediate payments solutions both in the US and Thailand as well as enabling access to the UK payments industry through their payments gateway solution PayPort. The business also saw the launch of the new image based cheque clearing system, creating a robust and more efficient system in the UK. RTP ® in the US: This week, Vocalink announced the launch of RTP® (Real-Time Payments) in the US on behalf of The Clearing House; one of the most comprehensive real-tim
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom